RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Completed · Phase 2

Conditions studied: Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery

In brief

This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.

Key facts

Study ID

NCT02128113

Run by

Biogen

People needed

307

Starts

2014-05-31

Expected to finish

2015-04-30

Last updated by the study team

2025-06-03

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be male or female and ≥18 years of age and ≤80 years of age
• Plan to undergo cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens
• Have the potential, in the opinion of the investigator, to improve best-corrected visual acuity in the study eye after surgery
• Have Grade 3, 4, or 5 nuclear cataract in the study eye, according to the LOCS III
• Have corneal endothelium in the study eye that can be accurately assessed using specular microscopy
• Have endothelial cell density of >1800 cells/mm2 in the study eye at the Screening Visit
• Have a pinhole visual acuity (VA) of at least 1.0 logarithm of the minimum angle of resolution (logMAR) in the study eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart

You may not qualify if…

• Have a score >0 on the ocular pain assessment at the Screening Visit or the Randomization Visit in the study eye
• Have an active immunosuppressive disease or an autoimmune disease that, in the opinion of the investigator, could affect the quality of the ocular surface
• Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing
• Have an intraocular pressure (IOP) ≤5 mmHg in either eye
• Have had corneal or retinal surgery (laser or incisional) within the past 6 months, or be planning to have laser or incisional surgery during the study period in the study eye
• Have the presence of guttae Stage 2 or greater or other abnormality in the study eye that does not allow for accurate corneal endothelial cell assessments

Where it is running

• Harvard Eye Associates — Laguna Hills, California, United States
• Hull Eye Center — Lancaster, California, United States
• Argus Research — Cape Coral, Florida, United States
• Levenson Eye Associates — Jacksonville, Florida, United States
• Chicago Cornea Consultants — Hoffman Estates, Illinois, United States
• JacksonEye — Lake Villa, Illinois, United States
• Discover Vision Centers — Leawood, Kansas, United States
• Opthalmic Consultants of Boston — Waltham, Massachusetts, United States
• Talamo Hatch Laser Eye Consultants — Waltham, Massachusetts, United States
• Associated Eye Care — Stillwater, Minnesota, United States
• Comprehensive Eye Care — Washington, Missouri, United States
• Alterman, Modi and Wolter — Poughkeepsie, New York, United States
• Cincinnati Eye Institute — Cincinnati, Ohio, United States
• R & R Eye Research — San Antonio, Texas, United States
• See Clearly Vision Group — McLean, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.